Otsuka Can Block Generic Abilify as Court Rejects Appeal

The U.S. Supreme Court left intact a ruling that lets Otsuka Holdings (4578)’s pharmaceutical unit block generic competition to its schizophrenia drug Abilify in the U.S. until April 2015.
Bloomberg